Skip to main content
Premium Trial:

Request an Annual Quote

German Shepherd's Own Sequence

Researchers have sequenced the genome of a German shepherd called Nala.

The dog genome was first published in 2005, but the researchers led by the University of New South Wales' Bill Ballard say that by examining the genome of this particular dog breed, they could generate a more complete view of dog genetics as well as have a reference for future studies into conditions affecting German shepherds.

Ballard notes that German shepherds are prone to developing hip dysplasia. "Because German shepherds make such good working dogs, there has been a lot of money spent looking into the causes and predictors of this problem," he says in a statement. "Now that we have the genome, we can determine much earlier in life whether the dog is likely to develop the condition."

As they report in GigaScience this week, Ballard and his colleagues sequenced Nala's genome using a combination of tools, including Pacific Bioscience, Oxford Nanopore, 10X Genomics, Bionano, and Hi-C technologies, to generate a highly contiguous genome.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.